Vision Research And Clinical Trials
Eye Care and Vision Research
research@vicolorado.com
Vision Institute is dedicated to conducting high-quality clinical trials as a way to discover new treatment alternatives. Our four clinicians specialize in the diagnosis and treatment of sight threatening diseases such as glaucoma, cataracts, and macular degeneration. Our doctors have numerous years of research history.
Our commitment is to our patients and patient care. The opportunity to participate in clinical trials allows us to discover new treatment options and access cutting edge technology.
Although some may think that research is done in a lab by a scientist that is not an accurate perception of clinical trials and the need for patient participation. Your participation is required in order for clinical trials to be conducted allowing introduction of new drugs and treatment options. Vision Institute takes great pride in efficiently conducting trials in an ethical, harmless, and efficient method to protect patient’s rights during the clinical process.
Our commitment is to our patients and patient care. The opportunity to participate in clinical trials allows us to discover new treatment options and access cutting edge technology.
Although some may think that research is done in a lab by a scientist that is not an accurate perception of clinical trials and the need for patient participation. Your participation is required in order for clinical trials to be conducted allowing introduction of new drugs and treatment options. Vision Institute takes great pride in efficiently conducting trials in an ethical, harmless, and efficient method to protect patient’s rights during the clinical process.
Research Department Staff
Blake Simmons, O.D. FAAO - Erik Anderson, MD -
Helene Agbo – Clinical Research Coordinator
Logan McConnell – Clinical Research Assistant
Helene Agbo – Clinical Research Coordinator
Logan McConnell – Clinical Research Assistant
Active & Upcoming Studies
June 2021: A phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenterstudy of the safety and efficacy of OT-101 (Atropine Sulfate 0.01%) in treating the progression of myopia in pediatric patients. – recruitment ongoing
July 2021: A Multi- Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease – recruiting now
July 2021: A randomized, controlled, multicenter, double-masked, parallel, phase 3 trial to evaluate the safety and efficacy of TP-03 for the treatment of demodex blepharitis – recruiting now
Future Studies
New Studies Coming Soon for the following indications: Dry Eye Disease and Allergic Conjunctivitis.
New Studies Coming Soon for dry eye disease and neurotrophic keratitis.
We are constantly looking for and starting new studies for various eye conditions, please contact our clinical research department at 719-559-2020 Ext#115 or #116 for information about our current opportunities.
June 2021: A phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenterstudy of the safety and efficacy of OT-101 (Atropine Sulfate 0.01%) in treating the progression of myopia in pediatric patients. – recruitment ongoing
July 2021: A Multi- Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease – recruiting now
July 2021: A randomized, controlled, multicenter, double-masked, parallel, phase 3 trial to evaluate the safety and efficacy of TP-03 for the treatment of demodex blepharitis – recruiting now
Future Studies
New Studies Coming Soon for the following indications: Dry Eye Disease and Allergic Conjunctivitis.
New Studies Coming Soon for dry eye disease and neurotrophic keratitis.
We are constantly looking for and starting new studies for various eye conditions, please contact our clinical research department at 719-559-2020 Ext#115 or #116 for information about our current opportunities.
Closed and Completed Studies
2019: “A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease”.
2019: Ophthalmic assessments of Signs and Symptoms of Dry eye in Patients Suffering from Self-Reported or Clinician-Diagnosed Dry Eye Disease.
2017: A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients with a Chalazion
2017: The objective of this study is to assess the safety and efficacy of RGN-259 Ophthalmic Solution compared to placebo for the treatment of Neurotrophic Keratitis
2017: A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye: ARISE-2
2017: A prospective, targeted, non-interventional (observation) study of subjects who developed corneal deposits in clinical trials – Vision Institute, Colorado Springs, CO Aerie Pharmaceuticals Phase III–Glaucoma/Cornea Study (not recruiting)
2016: A prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to AR-13324 Ophthalmic Solution, 0.02% and latanoprost Ophthalmic Solution, 0.005% in subjects with elevated intraocular pressure – Vision Institute, Colorado Springs, CO Aerie Pharmaceuticals Phase III–Glaucoma
2015: This study will evaluate a new ophthalmic formulation of cyclosporine in patients with moderate to severe dry eye disease in two stages.– Vision Institute, Colorado Springs, CO Allergan Phase II–Dry Eye Study
2015: A Randomized, Double-masked, Vehicle-controlled Study of LME636 in the Relief of Persistent Ocular Discomfort in Patients With Severe Dry Eye Disease– Vision Institute, Colorado Springs, CO Phase II–Dry Eye Study
2014-2015: Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution– Vision Institute, Colorado Springs, CO Aerie Pharmaceuticals Phase III–Glaucoma Study
2011-2012: A Phase 3 Multicenter, Randomized, Controlled, Double-Masked Study of Safety and Efficacy of Sodium Hyaluronate Ophthalmic Solution, 0.18% in Dry Eye Syndrome– St. Luke’s Eye Care & Laser Center, Colorado Springs, CO Alcon–Dry Eye Study
2009: The purpose of this study is to determine whether AL-38583 ophthalmic solution is effective for treatment of signs and symptoms of dry eye.– St. Luke’s Eye Care & Laser Center, Colorado Springs, CO Alcon Phase II –Dry Eye Study
2009: Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN®– St. Luke’s Eye Care & Laser Center, Colorado Springs, CO Alcon Phase 4 –Ocular Surface Effect
2009: Alcon C-08-034 -Dry Eye Study– St. Luke’s Eye Care & Laser Center, Colorado Spring, CO
2008-2009: Alcon C-07-015 –Dry Eye Study – St. Luke’s Eye Care & Laser Center, Colorado Springs, CO
2007: A Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates– St. Luke’s Eye Care & Laser Center, Colorado Springs, CO Alcon C-05-04 Phase II –Corneal Infiltrate Study
2007: A double masked study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.– St. Luke’s Eye Care & Laser Center, Colorado Springs, CO Alcon C-05-31 Phase II B –Dry Eye Study
1998: Allergan Phase II –Cyclosporine A – St. Luke’s Eye Care & Laser Center, Colorado Springs, CO
1996-1997: Pharmacia Phase III –Latanoprost – St. Luke’s Eye Care & Laser Center, Colorado Springs, CO
1993: Research –Effects of Cigarette Smoking on Results of Automated Standard Perimetry
2019: “A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease”.
2019: Ophthalmic assessments of Signs and Symptoms of Dry eye in Patients Suffering from Self-Reported or Clinician-Diagnosed Dry Eye Disease.
2017: A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients with a Chalazion
2017: The objective of this study is to assess the safety and efficacy of RGN-259 Ophthalmic Solution compared to placebo for the treatment of Neurotrophic Keratitis
2017: A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye: ARISE-2
2017: A prospective, targeted, non-interventional (observation) study of subjects who developed corneal deposits in clinical trials – Vision Institute, Colorado Springs, CO Aerie Pharmaceuticals Phase III–Glaucoma/Cornea Study (not recruiting)
2016: A prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to AR-13324 Ophthalmic Solution, 0.02% and latanoprost Ophthalmic Solution, 0.005% in subjects with elevated intraocular pressure – Vision Institute, Colorado Springs, CO Aerie Pharmaceuticals Phase III–Glaucoma
2015: This study will evaluate a new ophthalmic formulation of cyclosporine in patients with moderate to severe dry eye disease in two stages.– Vision Institute, Colorado Springs, CO Allergan Phase II–Dry Eye Study
2015: A Randomized, Double-masked, Vehicle-controlled Study of LME636 in the Relief of Persistent Ocular Discomfort in Patients With Severe Dry Eye Disease– Vision Institute, Colorado Springs, CO Phase II–Dry Eye Study
2014-2015: Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution– Vision Institute, Colorado Springs, CO Aerie Pharmaceuticals Phase III–Glaucoma Study
2011-2012: A Phase 3 Multicenter, Randomized, Controlled, Double-Masked Study of Safety and Efficacy of Sodium Hyaluronate Ophthalmic Solution, 0.18% in Dry Eye Syndrome– St. Luke’s Eye Care & Laser Center, Colorado Springs, CO Alcon–Dry Eye Study
2009: The purpose of this study is to determine whether AL-38583 ophthalmic solution is effective for treatment of signs and symptoms of dry eye.– St. Luke’s Eye Care & Laser Center, Colorado Springs, CO Alcon Phase II –Dry Eye Study
2009: Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN®– St. Luke’s Eye Care & Laser Center, Colorado Springs, CO Alcon Phase 4 –Ocular Surface Effect
2009: Alcon C-08-034 -Dry Eye Study– St. Luke’s Eye Care & Laser Center, Colorado Spring, CO
2008-2009: Alcon C-07-015 –Dry Eye Study – St. Luke’s Eye Care & Laser Center, Colorado Springs, CO
2007: A Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates– St. Luke’s Eye Care & Laser Center, Colorado Springs, CO Alcon C-05-04 Phase II –Corneal Infiltrate Study
2007: A double masked study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.– St. Luke’s Eye Care & Laser Center, Colorado Springs, CO Alcon C-05-31 Phase II B –Dry Eye Study
1998: Allergan Phase II –Cyclosporine A – St. Luke’s Eye Care & Laser Center, Colorado Springs, CO
1996-1997: Pharmacia Phase III –Latanoprost – St. Luke’s Eye Care & Laser Center, Colorado Springs, CO
1993: Research –Effects of Cigarette Smoking on Results of Automated Standard Perimetry
Clinical Trials
(Visit www.ClinicalTrials.gov for additional detail)
New Studies Coming Soon for the following indications: Glaucoma, Cataracts, Chalazion, Neurotrophic Keratitis, and Dry eye syndrome
We are constantly looking for and starting new studies for various eye conditions, please contact our clinical research department at 719-559-2020 Ext#116 for information about our current opportunities.
(Visit www.ClinicalTrials.gov for additional detail)
New Studies Coming Soon for the following indications: Glaucoma, Cataracts, Chalazion, Neurotrophic Keratitis, and Dry eye syndrome
We are constantly looking for and starting new studies for various eye conditions, please contact our clinical research department at 719-559-2020 Ext#116 for information about our current opportunities.
Participant Application For Open Vision Clinical Trials
We are constantly looking for and starting new studies for various eye conditions, please contact our clinical research department at 719-559-2020 Ext#116 for information about our current opportunities.
If you feel you are a good candidate and are interested in participating in a clinical trial please fill out the participant application.
|
Participant Application
|
|
|